Gold standard or wrong standard?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 271-272

  Oldham, Robert ^a   Dillman, Robert ^a  

^a Lewis Hall Singletary Oncol Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE PLUS INTERFERON; IMATINIB; INTERFERON; PENTOSTATIN; UNCLASSIFIED DRUG;

CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; EDITORIAL; HAIRY CELL LEUKEMIA; LYMPHOMA; MEDICAL LITERATURE; PRIORITY JOURNAL; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PIPERAZINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3142776343     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041425034     Document Type: Editorial

References (12)

1. Benzon K, Hartz AJ. Comparison of observational studies and randomized controlled trials. N Engl J Med 2000;342:1878.
2. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research design. N Engl J Med 2000;342:1887.
3. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations. N Engl J Med 2000;342:1907.
4. Dillman RO, Soori G, Wiemann MC, et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenous chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: Final results of Cancer Biotherapy Research group 94-11. Cancer Biother Radiopharm 2000;15:487.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cis-platin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 1999;17:968.
6. O'Brien SG, Guilhot F, Lawson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994.
7. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348(13):1048.
8. Branford S, Walsh S, Rudzki Z, et al. Imatinib produces significantly superior molecular responses compared to interferon plus low-dose Ara-C in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2002;100:96a.
9. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423.
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825.
11. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy-cell leukemia: An intergroup study. J Clin Oncol 1995;13:974.
12. Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1989;7:1533.